Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. That was above its estimated range of 15 to 17.
The stock closed at an all-time high on Feb. 21, 2020.
Is it too late to make a lot of money by investing in Guardant Health? The company develops and sells blood-based diagnostic tests aimed at understanding the molecular profiles of cancer patients' tumors.
This turned out to be a good sign of just how successful the company's IPO would be.Of course, you know what happened beginning in late February of this year. $515M. When they arrive on the scene, investors flock to them.
Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Form S-1 Guardant Health, Inc. General form for registration of securities under the Securities Act of 1933.
At that point, an initial investment of $10,000 in Guardant Health's IPO would have been worth $46,714.Guardant Health thinks that its Guardant360 liquid biopsy has a $6 billion addressable annual market in the U.S. alone.
About Form S-1. Guardant Health Stock.
Investors scoop up shares because of a fear of missing out.An even greater opportunity for Guardant Health, though, lies with its LUNAR liquid biopsies, which are currently available for research use only. I think that this stock has the kind of X factor that every investor should like.During 2019, Guardant Health's share price more than doubled. All of the shares of common stock are being offered by Guardant Health.In addition, Guardant Health has granted the underwriters a 30-day option to … LUNAR-2 has a much larger addressable market of more than $30 billion.Guardant Health delivered these tremendous gains the old-fashioned way. guardantfollow-onsx1.htm Zoom In Zoom Out. In its third-quarter earnings update, Guardant Health reported that it completed 13,259 of these tests for clinical customers.Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.Most everyday investors don't have the luxury of receiving IPO shares and must purchase shares during the first trading day. The potential U.S. market for LUNAR-1 is around $15 billion. Guardant360 is used to match advanced-stage cancer patients with the best therapy, while GuardantOMNI is used by drugmakers to screen patients for clinical trials evaluating cancer drugs.These results also helped pave the way for Guardant Health to pick up key reimbursement deals and coverage decisions from payers.
The market expects additional revenue from Guardant Health definitely has such an X factor.
The stock market plunged as the novel coronavirus and the disease that it causes, COVID-19, spread across the world. Guardant Health, Inc. Form S-1 (Filer) Published: 2019-05-20 16:14:46 Submitted: 2019-05-20.
When they arrive on the scene, investors flock to them.
Returns as of 07/30/2020.Certain stocks have an X factor. Why? I don't think so.The key to this success was the skyrocketing demand for Guardant Health's two liquid biopsy products, Guardant360 and GuardantOMNI. Why? Other peers are trading at cheaper valuations. Returns as of 07/30/2020.Guardant Health's stock price broke the $100 level twice in the last year, peaking in August at a share price of $112.
Assuming you could perfectly time the sale of your IPO initial shares, an investor theoretically could have amassed a 590% return in only 10 months. Guardant Health's shares sank as much as 34% off the highs from earlier in the year before rebounding.If Guardant Health can capture a significant share of these markets, its long-term returns could make the 360% gain since its IPO look like chump change. If investors bought at the opening trading price of $27.75 or at the first-day closing price of $32.20, a $10,000 investment would have grown to $26,760 or $23,062, respectively.
Founded.